Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: Results from the women's health initiative

Archives of Internal Medicine

Volumn 170, Issue 9, 2010, Pages 765-771

  Gray, Shelly L ^a   Lacroix, Andrea Z ^b   Larson, Joseph ^b   Robbins, John ^c   Cauley, Jane A ^d   Manson, Joann E ^e   Chen, Zhao ^f  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; BONE DENSITY; DISEASE ASSOCIATION; DRUG USE; FEMALE; FOREARM FRACTURE; FRACTURE; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; SPINE FRACTURE; WRIST FRACTURE;

AGED; BONE DENSITY; FEMALE; FRACTURES, SPONTANEOUS; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; OSTEOPOROSIS; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; RISK FACTORS; UNITED STATES;

EID: 77952115101     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2010.94     Document Type: Article

References (26)

1. 2008 Top 200 generic drugs by total prescriptions. Drug Topics Web site. http: //drugtopics.modernmedicine.com/drugtopics/data/articlestandard// drugtopics/192009/597086/article.pdf. Accessed June 17, 2009.
2. 2008 Top 200 branded drugs by total prescriptions. Drug Topics Web site. http: //drugtopics.modernmedicine.com/drugtopics/data/articlestandard// drugtopics/222009/599845/article.pdf. Accessed June 17, 2009.
3. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of nonsteroidal anti-inflammatory drugs, acetylsalicylic acid, and acetaminophen and the effects of rheumatoid arthritis and osteoarthritis. Calcif Tissue Int. 2006; 79(2):84-94. (Pubitemid 44306165)
4. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296(24):2947-2953. (Pubitemid 46021498)
5. Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179 (4):319-326.
6. Yu EW, Blackwell T, Ensrud KE, et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int. 2008;83(4):251-259.
7. Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy. 2008;28(8):951-959.
8. Grisso JA, Chiu GY, Maislin G, Steinmann WC, Portale J. Risk factors for hip fractures in men: a preliminary study. J Bone Miner Res. 1991;6(8):865-868.
9. Bone Health and Osteoporosis: a report of the Surgeon General, 2004. US Department of Health and Human Services Web site. http://www.surgeongeneral.gov/ library/bonehealth/content.html. Accessed June 17, 2009.
10. Langer RD, White E, Lewis CE, Kotchen JM, Hendrix SL, Trevisan M. The Women's Health Initiative observational study: baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol. 2003;13(9)(suppl 1):S107-S121.
11. Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials. 1998;19(1):61-109.
12. Chen Z, Kooperberg C, Pettinger MB, et al. Validity of self-report for fractures among a multiethnic cohort of postmenopausal women: results from the Women's Health Initiative observational study and clinical trials. Menopause. 2004; 11(3):264-274. (Pubitemid 40362180)
13. DXA quality assurance. National Heart, Lung, and Blood Institute Web site. https: //biolincc.nhlbi.nih.gov/static/studies/whios/doc/whi/procedur/ bone/1.pdf. Accessed July 6, 2009.
14. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36), I: conceptual framework and item selection. Med Care. 1992;30(6):473-483.
15. Ainsworth BE, Haskell WL, Leon AS, et al. Compendium of physical activities: classification of energy costs of human physical activities. Med Sci Sports Exerc. 1993;25(1):71-80.
16. Kristal AR, Feng Z, Coates RJ, Oberman A, George V. Associations of race/ ethnicity, education, and dietary intervention with the validity and reliability of a food frequency questionnaire: the Women's Health Trial Feasibility Study in Minority Populations. Am J Epidemiol. 1997;146(10):856-869. (Pubitemid 27498103)
17. Robbins J, Aragaki AK, Kooperberg C, et al. Factors associated with 5-year risk of hip fracture in postmenopausal women. JAMA. 2007;298(20):2389- 2398.
18. Bo-Linn GW, Davis GR, Buddrus DJ, Morawski SG, Santa Ana C, Fordtran JS. An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium. J Clin Invest. 1984;73(3):640-647.
19. Graziani G, Como G, Badalamenti S, et al. Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects. Nephrol Dial Transplant. 1995;10(8):1376-1380.
20. Graziani G, Badalamenti S, Como G, et al. Calcium and phosphate plasma levels in dialysis patients after dietary Ca-P overload: role of gastric acid secretion. Nephron. 2002;91(3):474-479.
21. Hardy P, Sechet A, Hottelart C, et al. Inhibition of gastric secretion by omeprazole and efficiency of calcium carbonate on the control of hyperphosphatemia in patients on chronic hemodialysis. Artif Organs. 1998;22(7):569-573.
22. Serfaty-Lacrosniere C, Wood RJ, Voytko D, et al. Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. J Am Coll Nutr. 1995;14 (4):364-368.
23. O'Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med. 2005;118(7):778-781.
24. Farina C, Gagliardi S. Selective inhibition of osteoclast vacuolar H(+)-ATPase. Curr Pharm Des. 2002;8(23):2033-2048.
25. Tuukkanen J, Vaananen HK. Omeprazole, a specific inhibitor of H+-K+-ATPase, inhibits bone resorption in vitro. Calcif Tissue Int. 1986;38(2):123-125.
26. Mizunashi K, Furukawa Y, Katano K, Abe K. Effect of omeprazole, an inhibitor of H+,K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int. 1993;53 (1):21-25. (Pubitemid 23187327)